Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: CD19 | Statement: [Juno Therapeutics, therapeuticTarget, CD19]

Target entity: CD19
Context triple: [Juno Therapeutics, therapeuticTarget, CD19]

• A. CD22
  CD22 is a B-cell–specific surface glycoprotein that functions as an inhibitory co-receptor modulating B cell receptor signaling and immune responses.
• B. CD21
  CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
• C. CD20 protein
  CD20 protein is a cell-surface antigen found primarily on B lymphocytes and is a key therapeutic target in certain autoimmune diseases and B-cell malignancies.
• D. CD46
  CD46 is a human cell-surface complement regulatory protein that also serves as an entry receptor for various pathogens, including certain adenoviruses and measles virus.
• E. CD38
  CD38 is a cell surface glycoprotein with ectoenzyme and receptor functions, highly expressed on plasma cells and targeted in therapies for multiple myeloma and other hematologic malignancies.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: CD19
Triple: [Juno Therapeutics, therapeuticTarget, CD19]

CD19 is a B-cell surface protein widely used as a key immunotherapy target in treatments for B-cell malignancies such as certain leukemias and lymphomas.

Target entity: CD19
Target entity description: CD19 is a B-cell surface protein widely used as a key immunotherapy target in treatments for B-cell malignancies such as certain leukemias and lymphomas.

• A. CD22
  CD22 is a B-cell–specific surface glycoprotein that functions as an inhibitory co-receptor modulating B cell receptor signaling and immune responses.
• B. CD21
  CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
• C. CD20 protein
  CD20 protein is a cell-surface antigen found primarily on B lymphocytes and is a key therapeutic target in certain autoimmune diseases and B-cell malignancies.
• D. CD46
  CD46 is a human cell-surface complement regulatory protein that also serves as an entry receptor for various pathogens, including certain adenoviruses and measles virus.
• E. CD38
  CD38 is a cell surface glycoprotein with ectoenzyme and receptor functions, highly expressed on plasma cells and targeted in therapies for multiple myeloma and other hematologic malignancies.
• F. None of above. chosen

Target predicate: therapeuticTarget
Context triple: [Juno Therapeutics, therapeuticTarget, CD19]

• A. regulatoryTarget
  Indicates that one entity is subject to control, influence, or governance by another entity under a regulatory or rule-based framework.
• B. hasMolecularTarget chosen
  Indicates that one entity (such as a drug or compound) is directed toward, binds to, or specifically interacts with a particular molecular target (such as a protein, receptor, or gene).
• C. hasTherapeuticGoal
  Indicates that an action, treatment, or intervention is undertaken with the intention of achieving a specific therapeutic or health-related outcome.
• D. potentialTherapeuticUse
  Indicates that something is being considered or investigated as a possible treatment or therapy for a condition or disease.
• E. hasTargetDisease
  Indicates that an entity (such as a treatment, study, or intervention) is directed toward, intended to affect, or primarily concerned with a specified disease.
• F. None of above.